BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

MEDIA

BIO Asia–Taiwan 2024 Kicks Off July 24th

Conference Expands into Three Tracks, Exhibition booths exceed 2,200

Domestic and International investment notables gather for Investment Summit

 

28 June, 2024

BIO Asia–Taiwan 2024, jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO), will be held July 24th to 28th at the Taipei Nangang Exhibition Center, TaiNEX 1 and 2. This year, the conference is expanding into three tracks, and the Exhibition is expected to host over 900 flagship companies utilizing 2,200 booths. The One-on-one Partnering program already has bookings from over 500 local and international companies looking for connection and collaboration opportunities. Participating in this year’s gathering includes many internationally-renowned companies and investment institutions. BIO Asia–Taiwan 2024 organizers urge potential participants to register early to secure business matching and negotiation opportunities.   

 

Chairman of the BIO Asia–Taiwan 2024 organizing committee, Johnsee Lee, stated that with this year—the sixth year of the gathering—exhibition bookings, forum participation, and registrations in the one-on-one partnering platform have all surpassed previous years. But the most noticeable difference is in the conference, which has this year expanded into three major tracks: A three-day Innovation Forum; a two-day Investment Summit, and a three-day Regional Cooperation Forum, with the three tracks running in parallel.

 

In the Investment Summit, a total of 50 investment-seeking companies from the US, Canada, the UK, Japan, Switzerland, South Korea, Lithuania, Slovenia, and Taiwan have been selected to give presentations. In addition to new drug development and digital healthcare, AI applications in clinical trials, and medical imaging companies are among those selected, with these fields currently under the investment spotlight. 

 

Interest from the international investment community in this summit is strong, with more than 50 investment entities from Japan, the United States, Taiwan, Singapore, Switzerland, the United Kingdom, and Israel expected to attend. These include the flagship American institution Flagship Pioneering, venture capital firms Prime Ventures, Vivo Capital, British venture capital firm Syncona, Israel's largest pharmaceutical venture capital fund aMoon, Pegasus Tech Ventures, Japan's DCI Partners, Axil Capital Partners, and others. 

 

The Innovative Forum will focus on some of the industry’s hottest topics, including regenerative medicine, ADC drugs, AI drug applications, mRNA drugs, CDMOs, biopharmaceuticals, translational medicine, precision health, and digital health. An impressive lineup of international speakers have been invited to share their insights, including Tom Diethe, head of the AstraZeneca AI Center, to discuss how advances in deep learning are driving drug development; Yusuke Nakamura, President of the National Institute of Biomedical Innovation, Health, and Nutrition (NIBIOHN) in Japan, who will discuss the latest new therapies; and Paru Deshpande, Vice President of Life Sciences Technologies at the Interuniversity Microelectronics Centre (IMEC) in Belgium, to discuss bioconvergence, the fusion of biology and technology.

 

With two major regenerative medicine laws recently passing their third and final reading and soon to become Taiwan law, BIO Asia–Taiwan 2024 has invited Miguel Forte, President of the International Society for Cellular Therapy (ISCT), an international professional organization dedicated to cell research, manufacturing, processing, and clinical transplantation, to speak at the Innovation Forum to share insight on global trends in regenerative medicine. Anticipating the strong potential for this field in Taiwan, many local and international cell and gene therapy companies have confirmed their participation in the exhibition, including Japan's Fujifilm, the UK's Syncona, and Taiwanese companies such as the newly-formed Taiwan Bio-Pharmaceutical Manufacturing Company (TBMC), Ever Supreme Bio Technology, Arce Therapeutics, Bionet, UnicoCell Biomed, Mitek Lab, ACRO Biomedical, ChainHome Biotech, Bertec Enterprise, and Supercell Biotech.

 

BIO Asia–Taiwan 2024 is jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO). This year's theme is 'Global View, Asian Touch,' focusing on global biotechnology business opportunities from an Asian viewpoint. The Conference includes three tracks; a three-day Innovation Forum; a two-day Investment Summit, and a three-day Regional Cooperation Forum, with BIO Asia–Taiwan also hosting an Exhibition, One-on-one Partnering, Company Presentations, and Themed Seminars.

 

The organizers urge potential attendees to seize the opportunity and register as soon as possible. Online registration is open until July 16. Please visit the BIO Asia–Taiwan 2024 website for more details. www.bioasiataiwan.com